好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pregnancy Outcomes and Disease Activity in Women With NMOSD and MOGAD
Multiple Sclerosis
P8 - Poster Session 8 (11:45 AM-12:45 PM)
20-006
To assess pregnancy outcomes and disease activity in women with NMOSD/MOGAD
Pregnancy information in women with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is scarce
66 pregnancies were documented in the German multiple sclerosis and pregnancy registry and the neuromyelitis optica study group registry. 34 pregnancies were collected prospectively and 32 reprospectively with standardized questionnaires during pregnancy and postpartum. Clinical data including relapses and adverse pregnancy outcomes were retrieved from the registries/treating physicians

Most women 44 (66.7%) were aquaporin-4 antibody positive (AQP4-Ab+), 2 (3.0%) AQP4-Ab negative (AQP4-Ab-) and 20 (30.3%) had MOGAD with a mean age of 31.4±5.2 years. 47/64 women (73.4%; n=30 AQP4-Ab+,n=2 AQP4-Ab-, n=15 MOGAD) were therapy exposed at conception: 31/64 (48.4%) to anti-CD20, 10/64 (15.6%) to azathioprine, 2/64 (3.1%) to glatirameracetate and one each (1.6%) to satralizumab, inebilizumab and tocilizumab.

In 63 known pregnancy outcomes (n=1 ongoing, n=2 lost to follow-up), 56 live births (88.9%) with a mean birthweight of 3311 (±501.7) grams, five (7.9%) spontaneous abortions and two (3.2%) elective abortions were reported. Three (5.4%) major congenital malformations occurred: peripheral pulmonary stenosis, persistent ductus arteriosus and osteogenesis imperfecta. Excluding two infants with missing data, 6/54 (11.1%) were preterm and 10/54 (18.5%) small for gestational age (SGA).

Only 4/63 (6.3%) relapses during pregnancy (DMT untreated and AQP4+) occurred. In patients with at least three-months follow-up, 14/56 (25.0%) relapsed in the first-year postpartum (n=7/36 (19.4%) AQP4-Ab+: 1/7 (14.3%) pretreated with azathioprine, 3/7 (42.9%) with rituximab and 3/7 (42.9%) untreated; n=7/18 (38.9%) MOGAD: 1/7 (14.3%) pretreated with azathioprine, 3/7 (42.9%) with rituximab and 3/7 (42.9%) untreated). Results will be stratified by disease for the meeting
Our findings provide valuable insights into pregnancies in women with NMOSD/MOGAD, with low disease activity in pregnancy and increase postpartum. Newborns were generally healthy with increased number of SGA
Authors/Disclosures
Kerstin Hellwig (St. Josef Hospital Bochum)
PRESENTER 		Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from BMS .
Nina Blum Miss Blum has nothing to disclose.
Karen I. Dost-Kovalsky Ms. Dost-Kovalsky has nothing to disclose.
Sina Roettger, MD Mrs. Roettger has nothing to disclose.
Saskia Wenzel, MD Mrs. Wenzel has nothing to disclose.
Sabrina Haben (St. Josef Hospital) Sabrina Haben has nothing to disclose.
Nadine Bast (St Josef Hospital) Mrs. Bast has received personal compensation in the range of $0-$499 for serving as a Manuscript Writer with Thieme Verlag.
Kaya Bayer, MSc Mrs. Bayer has nothing to disclose.
Achim Berthele (School of Medicine, Technical University Munich, Klinikum rechts der Isar, Dept.) Achim Berthele has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Achim Berthele has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuraxpharm. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sabofi. Achim Berthele has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Achim Berthele has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. Achim Berthele has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Achim Berthele has received publishing royalties from a publication relating to health care.
Tania Kuempfel, MD (Institut for Klinische Neuroimmunologie) Dr. Kuempfel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Kuempfel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Kuempfel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Kuempfel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Kuempfel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen/Horizon.
Marius Ringelstein Marius Ringelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Marius Ringelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
Orhan Aktas, MD (Neurologische Klinik) Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen/Horizon. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubish Tanake. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Aktas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen/Horizon. The institution of Dr. Aktas has received research support from German Research Foundation. The institution of Dr. Aktas has received research support from German Ministry of Science. The institution of Dr. Aktas has received research support from Neuromyelitis optica Study Group (NEMOS).
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology) The institution of Dr. Wildemann has received research support from Roche. The institution of Dr. Wildemann has received research support from Novartis. The institution of Dr. Wildemann has received research support from Argenx. Dr. Wildemann has received personal compensation in the range of $500-$4,999 for serving as a Conference participant with Neuraxpharm. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Soeaker with Instand.
Veit Rothhammer, MD (Universität Erlangen-Nuernberg) Prof. Rothhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Rothhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Prof. Rothhammer has received research support from German Research Foundation. The institution of Prof. Rothhammer has received research support from European Research Council.
Yavor Yalachkov Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Juvise. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen/Horizon. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Meyers Squibb. Dr. Yalachkov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuraxpharm. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Juvise. Dr. Yalachkov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Yalachkov has received research support from Deutsche Forschungsgemeinschaft . The institution of Dr. Yalachkov has received research support from Heinrich und Erna Schaufler Stiftung. The institution of Dr. Yalachkov has received research support from Novartis. The institution of Dr. Yalachkov has received research support from Roche. Dr. Yalachkov has received publishing royalties from a publication relating to health care. Dr. Yalachkov has received personal compensation in the range of $5,000-$9,999 for serving as a travel grant with Alexion. Dr. Yalachkov has received personal compensation in the range of $5,000-$9,999 for serving as a travel grant with Sanofi.
Martin Weber, MD (Universitätsmedizin Göttingen) Dr. Weber has nothing to disclose.
Luisa H. Klotz, MD (Uniklinik Münster) Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Klotz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Klotz has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Klotz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Klotz has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono. Dr. Klotz has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Klotz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Klotz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viatris. Dr. Klotz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Klotz has received research support from Immunic AG. The institution of Dr. Klotz has received research support from Merck.
Martin W. Hümmert, MD Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AMGEN. Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AMGEN. Dr. Hümmert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Hümmert has received research support from German Federal Joint Committee/Innovation Fund. The institution of Dr. Hümmert has received research support from NEMOS e. V..
Friedemann Paul (Charite Universitatsmedizin in Berlin) Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb GmbH & Co. KGaA (BMS. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics GmbH. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Paul has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Paul has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Paul has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for F&U Confirm. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb GesmbH. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MICE Service. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for VINDICO medical education. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Beijing Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sandoz Internation GmbH. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Thailand. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche . Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology, Neuroimmunology&Neuroinflammation.
Jasmin Naumann, MD Dr. Naumann has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Merck, Biogen; BMS, Roche.
Marina Herwerth, MD Dr. Herwerth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Herwerth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Herwerth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Herwerth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Herwerth has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Herwerth has received research support from Roche. The institution of Dr. Herwerth has received research support from SNSF. The institution of Dr. Herwerth has received research support from Swiss MS Society. The institution of Dr. Herwerth has received research support from Olga-Mayenfisch-Foundation. Dr. Herwerth has received publishing royalties from a publication relating to health care.
Vivien Häußler, MD Dr. Häußler has nothing to disclose.
Ilya Ayzenberg (Ruhr-Universitat Bochum) Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Aventis. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Ayzenberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. The institution of Dr. Ayzenberg has received research support from Diamed.
Sandra Thiel (Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany) Ms. Thiel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer Healthcare .